Browse articles from EyeWorld.org related to IOLs. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
There are many motives and methods for IOL exchange. While a rare need, the physicians who spoke with EyeWorld about best practices in this area said it’s important—especially if using advanced technology IOLs—to be familiar with the indications for exchange, removal techniques, and considerations for IOL replacement.
This article recaps the 2023 Richard L. Lindstrom, MD, Lecture, titled “Glaucoma Surgery: Taking it to the Next Level,” given by Marlene Moster, MD, as well as the other presentations in the session, given by Cathleen McCabe, MD, Francis Mah, MD, and Daniel Chang, MD.
The cataract patient who has had prior refractive surgery requires extra considerations in terms of consultations/patient expectations, IOL selection, formulas, use of intraoperative technologies, and postoperative potential. Two experts provided their thoughts on the modern management of these cataract patients.
Two physicians who have studied and used light-blocking and light-filtering IOL technology in clinical practice discussed with EyeWorld the concepts behind blocking and filtering certain violet and blue light.
Monday on the Main Stage at the ASCRS Annual Meeting featured the Charles D. Kelman, MD, Innovator’s Lecture, by William Link, PhD, and several other presentations on innovations from Sergio Canabrava, MD, Mark Lobanoff, MD, Richard Lewis, MD, Forrest Ellis, MD, and Elizabeth Yeu, MD.
➤ Phase 1/2 trial to evaluate intravitreal implant to delay cataract progression ➤ Update from Phase 1/2 proof-of-concept trial for chronic TED treatment ➤ First patient dosed for investigational, oral geographic atrophy treatment ➤ Pediatric study for pain, inflammation treatment following ocular surgery ➤ Complimentary access to video journal ➤ ASCRS news and events
➤ Enrollment complete in MIGS pivotal trial ➤ Acquisition of dry eye drop ➤ Two-year results post-cilio-scleral glaucoma procedure ➤ Positive topline results from Phase 2 study of retinitis pigmentosa treatment ➤ ASCRS news and events
➤ Study evaluates safety of office-based lens surgery ➤ FDA issues response to BLA for 8 mg aflibercept ➤ Pre-clinical data for non-viral gene therapy ➤ Non-human primate study of dry AMD therapy ➤ Expanded insurance coverage for MIGS procedures ➤ ASCRS news and events
➤ Phase 2 trial with experimental geographic atrophy treatment shows preservation of visual function ➤ AI-enabled screening system receives FDA clearance ➤ Enrollment complete for study evaluating investigational first-line therapy for DME ➤ Updates from two retinitis pigmentosa trials ➤ ASCRS news and events
➤ FDA approves dry eye drop targeting tear evaporation ➤ Topline results from Phase 3 trial of eye drops for DME ➤ Investigational intravitreal gene therapy program introduced for geographic atrophy ➤ Phase 1 study for periocular drug for wet AMD and DME begins ➤ Commercial rights for uveitis treatment acquired ➤ ASCRS news and events